Navigation Links
Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
Date:9/1/2013

Dallas, Texas (PRWEB) September 01, 2013

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication – Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last five years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Get a copy of the complete report with comprehensive Table of Contents @ http://www.reportsnreports.com/reports/267697-treating-refractory-hematological-malignancies-myelodysplastic-syndromes-mds-and-acute-myeloid-leukemia-aml-emerging-therapeutics.html.

Reasons to buy the report :
Useful for investors, Scientists, Business development managers of Pharma companies with a focus in oncology to address the following-

  •     What are the opportunities or new approaches to be deployed in the R&D of the company?
  •     List of validated and new targets
  •     In-licensing opportunities – Is the way to go forward and be in the race?
  •     Commercial opportunity and companies’ valuation.

Key Points Discussed in the Report –
1.    Overview of the disease and Unmet need
2.    Drugs in the pipeline – Mechanism of Action (MoA) and Clinical Stage of development
a.    Myelodysplastic Syndromes – Lower-risk, Higher-risk, and recurrent / refractory MDS
b.    Acute Myeloid Leukemia – Untreated/ newly diagnosed and relapsed / refractory AML
3.    Key milestones
4.    Launch Timeline and Commercial Opportunity of Late-stage pipeline (RR MDS and RR AML)
5.    M&A and Licensing deals in the last 5 years
6.    In-licensing and/or M&A Opportunity
7.    Detailed Company analysis includes Clinical data of drugs , Milestones and Valuation for Ambit Biosciences (AMBI), Onconova Therapeutics (ONTX), Celgene (CELG) and SymBio (4582).

Place a direct purchase order @ http://www.reportsnreports.com/Purchase.aspx?name=267697
Alternatively inquire for discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=267697

Explore above and other reports by MP Advisors @ http://www.reportsnreports.com/publisher/mp-advisors/

About Us:

ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers. Our database includes reports by leading publishers from across the globe. We also offer custom research services in case your requirements are not covered in the available syndicated market research reports in our database.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11078237.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
3. N-Butanol Market (Butyl Acrylate, Butyl Acetate, Glycol Ethers) worth $9.4 Billion by 2018 - New Report by MarketsandMarkets
4. Global Proteomics Market (Instrumentation Technology, Reagents & Services) Worth $17.2 Billion by 2017 - New Report by MarketsandMarkets
5. The Global Ophthalmology Devices and Drugs Market is Expected to Reach $52.6 Billion by 2017 - New Report by MarketsandMarkets
6. Contrast Media / Contrast Agents Market (Interventional Radiology & Interventional Cardiology) worth $8.6 Billion by 2017 - New Report by MarketsandMarkets
7. Transformer Oil Market (Mineral Oil - Naphthenic & Paraffinic) Worth $2.46 Billion by 2017 - New Report by MarketsandMarkets
8. Therapeutic Partnering Market Trends with 2013 Analysis in New Research Report at ReportsnReports.com
9. Telerad Tech's RADSpa™ Announces Its Entry Into Brazil Markets
10. Flight Management Systems Market (Flight Management Computer, Flight Management Control Unit) Worth $1.8 Billion By 2018 – New Report by MarketsandMarkets
11. Slimming Kou Tea: The Newest Weight Loss Tea Released in the Market With 1 Month Extra Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... W.S. ... products, has been honored with a 2016 When Work Works Award for its use ... part of the national When Work Works project administered by the Families and Work ...
(Date:5/26/2016)... ... , ... On Memorial Day, Hope For Heroes and USA Medical ... for the country. The nonprofit Hope For Heroes partnered with the leading provider ... for disabled military veterans, as well as police, firemen, and EMS professionals across the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... Indianapolis, Indiana (PRWEB) , ... May 26, 2016 ... ... national provider of healthcare supply chain solutions, today announced the organization has earned ... management meets international standards and is compliant with all rules and policies associated ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... founder of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), ... and Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25, 2016 Inivata, ... precision of circulating tumour DNA (ctDNA) analysis to ... appointment of Professor Clive Morris as ... across the clinical development programme, scientific collaborations, and ... deliver significant improvements in clinical outcomes for patients. ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... VMS BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , ... the company,s business development and sales team, exploring new opportunities for VMS to empower ... ... ... ...
Breaking Medicine Technology: